Skip to main content

CD79A Antibody (IGA/1406)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-53254

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-53254-100ug
NBP2-53254-20ug

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG3 Kappa Clone # IGA/1406

Concentration

0.2 mg/ml

Product Specifications

Immunogen

A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79A protein. (Uniprot: P11912)

Localization

Cell surface

Specificity

A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

Marker

B-Cell Marker

Clonality

Monoclonal

Host

Mouse

Isotype

IgG3 Kappa

Description

200ug/ml of antibody purified from Bioreactor Concentrate by Protein A or G. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0 mg/ml. (NBP2-54370)

Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.

Scientific Data Images for CD79A Antibody (IGA/1406)

Western Blot: CD79A Antibody (IGA/1406) [NBP2-53254]

Western Blot: CD79A Antibody (IGA/1406) [NBP2-53254]

Western Blot: CD79A Antibody (IGA/1406) [NBP2-53254] - Western Blot of Ramos Cell Lysate using CD79a Monoclonal Antibody (IGA/1406).

Applications for CD79A Antibody (IGA/1406)

Application
Recommended Usage

Flow Cytometry

1-2 ug/million cells

Immunocytochemistry/ Immunofluorescence

1-2 ug/ml

Western Blot

1-2 ug/ml
Application Notes
Optimal dilution for a specific application should be determined.
Western Blot: 1-2ug/ml. Optimal dilution for a specific application should be determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

10 mM PBS with 0.05% BSA

Preservative

0.05% Sodium Azide

Concentration

0.2 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: CD79A

CD79a is a disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells to constitute the B cell Ag receptor. CD79a first appears at pre B cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines.

Alternate Names

CD79A, MB-1

Gene Symbol

CD79A

UniProt

Additional CD79A Products

Product Documents for CD79A Antibody (IGA/1406)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for CD79A Antibody (IGA/1406)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...